AZD8421

DRUG2 trials

Sponsors

Astrazeneca AB, AstraZeneca

Conditions

ER+ HER2- Advanced Breast CancerHigh-grade Serous Ovarian Cancer (HGSOC)Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)

Phase 1

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

RecruitingNCT06188520

AstraZenecaER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

Start: 2023-12-05End: 2027-08-04Target: 564Updated: 2026-02-24

A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants with Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

RecruitingCTIS2023-507305-33-00

Astrazeneca ABPatients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)

Start: 2024-04-29Target: 28Updated: 2026-01-22

Related Papers

Abstract ND06: First disclosure of AZD8421, a highly selective CDK2 inhibitor to address resistance to CDK4/6 inhibitors in breast and CCNE1-high cancers

Cancer Research2024-04-059 citations